CHICAGO — Clive Morris, MD, CEO of Inivata, spoke with HemOnc Today at ASCO Annual Meeting about the company’s efforts to develop new clinical applications for liquid biopsy and circulating tumor DNA analysis.
Company data presented at ASCO further clarified the role of circulating tumor DNA in advanced lung cancer, Morris said.
One study examined how the distribution of tumors can affect levels of circulating tumor DNA, particularly for patients with central nervous system metastases.
Another study assessed how the pattern of resistance mutations among patients treated with ALK inhibitors can affect sensitivity to different therapeutics, as well as long-term patient outcomes.
The company’s first product is now reimbursed in the United States for Medicare recipients with advanced non-small cell lung cancer to help guide appropriate therapy.
Company officials are excited about the potential of their technology moving into earlier-stage cancers, Morris told HemOnc Today.
“This is a really exciting time for liquid biopsy,” Morris said. “We really are moving from the era of research and people hoping these tools may be useful ... to actually using them routinely for patients day in and day out in oncology practices.” by Mark Leiser